Healthpoint UAE

healthpoint.ae

Healthpoint is a specialty hospital in Abu Dhabi. It has three Centers of Excellence – Musculoskeletal, encompassing Orthopedics & Sports Medicine and Wooridul Spine; the Bariatric & Metabolic Surgery Centre and the Dental Clinic – each working in integrated practice units with supporting services to create a world-class hospital experience.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

AI

VIVA BIOTECH AND BIOMAP HAVE SIGNED A STRATEGIC COLLABORATION AGREEMENT TO ACCELERATE EARLY DRUG DISCOVERY USING AI TECHNOLOGY

Viva Biotech, BioMap | May 11, 2021

news image

The first generation of the China Biocomputing Conference, hosted by BioMap and Adock, was successfully launched in Suzhou. The conference's goal is to bring together biotech and IT industry partners to build a multi-party integrated industrial ecosystem and realize AI's full potential in the field of biotechnology. Viva Biotech was invited to the conference and announced a strategic alliance with BioMap. This alliance will combine BioMap's AI + biological computing en...

Read More

Cell and Gene Therapy

AMYRIS PARTNERS WITH INSCRIPTA TO ENHANCE DEVELOPMENT OF SUSTAINABLE INGREDIENTS USING THE ONYX™ GENOME ENGINEERING PLATFORM

Amyris | October 06, 2021

news image

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced that Amyris has licensed the Onyx genome engineering platform from Inscripta, a leading gene editing technology company. Amyris and Inscripta will also explore joint research and development opportunities to expand the Onyx platform functionality. Amyris' prod...

Read More

Medical

MERCK ENTERS INTO SUPPLY AGREEMENT WITH U.S. GOVERNMENT TO MANUFACTURE AND INITIAL DISTRIBUTION OF INVESTIGATIONAL BIOLOGICAL THERAPEUTIC

Merck | December 28, 2020

news image

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today declared it has gone into a agreement with the United States Government to help the turn of events, assembling and introductory dispersion of an investigational biological therapeutic (CD24Fc, to be named MK-7110) upon endorsement or Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). Merck acquired MK-7110 through the securing of OncoImmune, a privately held, clinical-stage biopharmaceuti...

Read More

Industry Outlook

CRESILON RECEIVES FIRST FDA CLEARANCE FOR HUMAN USE OF HEMOSTATIC GEL TECHNOLOGY

PRNewswire. | July 03, 2023

news image

Cresilon, Inc. a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, announced that it has been granted 510(k) clearance from the U.S. Food and Drug Administration ("FDA") for Cresilon Hemostatic Gel™ ("CHG™"). This marks Cresilon's first FDA clearance for human use, validating its revolutionary hemostatic gel technology and the company's global mission to transform wound care. CHG™ util...

Read More
news image

AI

VIVA BIOTECH AND BIOMAP HAVE SIGNED A STRATEGIC COLLABORATION AGREEMENT TO ACCELERATE EARLY DRUG DISCOVERY USING AI TECHNOLOGY

Viva Biotech, BioMap | May 11, 2021

The first generation of the China Biocomputing Conference, hosted by BioMap and Adock, was successfully launched in Suzhou. The conference's goal is to bring together biotech and IT industry partners to build a multi-party integrated industrial ecosystem and realize AI's full potential in the field of biotechnology. Viva Biotech was invited to the conference and announced a strategic alliance with BioMap. This alliance will combine BioMap's AI + biological computing en...

Read More
news image

Cell and Gene Therapy

AMYRIS PARTNERS WITH INSCRIPTA TO ENHANCE DEVELOPMENT OF SUSTAINABLE INGREDIENTS USING THE ONYX™ GENOME ENGINEERING PLATFORM

Amyris | October 06, 2021

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced that Amyris has licensed the Onyx genome engineering platform from Inscripta, a leading gene editing technology company. Amyris and Inscripta will also explore joint research and development opportunities to expand the Onyx platform functionality. Amyris' prod...

Read More
news image

Medical

MERCK ENTERS INTO SUPPLY AGREEMENT WITH U.S. GOVERNMENT TO MANUFACTURE AND INITIAL DISTRIBUTION OF INVESTIGATIONAL BIOLOGICAL THERAPEUTIC

Merck | December 28, 2020

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today declared it has gone into a agreement with the United States Government to help the turn of events, assembling and introductory dispersion of an investigational biological therapeutic (CD24Fc, to be named MK-7110) upon endorsement or Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). Merck acquired MK-7110 through the securing of OncoImmune, a privately held, clinical-stage biopharmaceuti...

Read More
news image

Industry Outlook

CRESILON RECEIVES FIRST FDA CLEARANCE FOR HUMAN USE OF HEMOSTATIC GEL TECHNOLOGY

PRNewswire. | July 03, 2023

Cresilon, Inc. a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, announced that it has been granted 510(k) clearance from the U.S. Food and Drug Administration ("FDA") for Cresilon Hemostatic Gel™ ("CHG™"). This marks Cresilon's first FDA clearance for human use, validating its revolutionary hemostatic gel technology and the company's global mission to transform wound care. CHG™ util...

Read More

Resources

resource image

Industry Outlook

Biopharmaceutical Sector

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us